PROSUS 39.190 € (-0,75 %)
INPOST 15.490 € (+0,13 %)
WORLDLINE 9.519 € (-1,07 %)
CARREFOUR 16.640 € (+0,15 %)
VEOLIA ENVIRON. 37.460 € (+1,38 %)
COMPAGNIE ODET 1 438.000 € (-1,10 %)
CSG 14.056 € (+6,23 %)
ASML HOLDING 1 555.800 € (+0,97 %)
LEGRAND 142.000 € (+1,97 %)
PHILIPS KON 23.010 € (-4,48 %)
ADP 109.100 € (-2,06 %)
AALBERTS NV 40.000 € (+1,01 %)
V LANSCHOT KEMPEN 67.300 € (+0,67 %)
CRCAM SUD R.A.CCI 217.000 € (-0,46 %)
SHELL PLC 36.865 € (+0,99 %)
TECHNIP ENERGIES 32.980 € (-0,30 %)
NN GROUP 77.480 € (+1,81 %)
RENAULT 25.840 € (-1,30 %)
CAPGEMINI 90.140 € (-1,62 %)
APERAM 46.860 € (-0,68 %)
ARCELORMITTAL SA 58.720 € (+1,17 %)
DSM FIRMENICH AG 84.940 € (+1,34 %)
ING GROEP N.V. 28.745 € (+1,14 %)
BE SEMICONDUCTOR 251.600 € (+1,86 %)
HEINEKEN 75.840 € (+0,05 %)
AHOLD DEL 36.120 € (+1,46 %)
UNILEVER 53.530 € (-0,50 %)
RELX 28.800 € (-1,44 %)
KPN KON 4.345 € (+0,25 %)
WOLTERS KLUWER 61.260 € (-1,89 %)
IMCD 91.580 € (+6,24 %)
AEGON 7.836 € (+1,79 %)
SBM OFFSHORE 32.100 € (-0,74 %)
MAGNUM 16.306 € (+0,27 %)
QUADIENT 11.960 € (-0,83 %)
SOITEC 102.750 € (+5,00 %)
PLANISWARE 20.650 € (-1,67 %)
SYNERGIE 28.100 € (-0,35 %)
AKZO NOBEL 57.340 € (-0,24 %)
AIR LIQUIDE 178.520 € (+1,01 %)
PERNOD RICARD 63.480 € (-1,15 %)
ASM INTERNATIONAL 927.600 € (+4,27 %)
SPIE 47.900 € (+0,42 %)
NANOBIOTIX 36.200 € (+3,61 %)
FORVIA 8.980 € (-2,79 %)
LVMH 482.950 € (-1,74 %)
HEIJMANS KON 96.150 € (-0,77 %)
SAINT GOBAIN 74.620 € (-0,35 %)
VALERIO TX 0.429 € (+7,25 %)
ADYEN 827.500 € (-1,92 %)
MICHELIN 34.180 € (-1,58 %)
LIGHTON 5.060 € (-4,71 %)
BENETEAU 6.080 € (-0,82 %)
KERING 244.250 € (-2,44 %)
TOTALENERGIES 71.200 € (+1,11 %)
IPSOS 35.360 € (+0,57 %)
BNP PARIBAS ACT.A 102.320 € (+1,39 %)
CAFOM 13.300 € (-3,62 %)
ESSILORLUXOTTICA 165.150 € (-2,51 %)
MAROC TELECOM 8.800 € (0,00 %) |
28/04/2023 11:00
Asklepios Kliniken: Solid performance in 2022EQS-News: Asklepios Kliniken / Key word(s): Annual Report Asklepios Group: Solid performance in 2022 Hamburg, 28 April 2023. 2022 was a challenging financial year for Asklepios Kliniken GmbH & Co. KGaA that was dominated by global political and economic developments. The Asklepios Group’s healthcare facilities treated around 3.6 million patients in the 2022 financial year, a slight increase on the previous year (2021: 3.5 million). The Asklepios Group generated revenue of EUR 5.3 billion in the 2022 financial year (previous year: EUR 5.1 billion). Consolidated net operating income (EAT) amounted to EUR 131.9 million (2021: 106.3 million). Capital expenditure totalled EUR 314.0 million in the 2022 financial year (2021: EUR 332.6 million), while the internal financing ratio amounted to 69.5% (2021: 72.8%). The Asklepios Group enjoyed a stable financial position at the end of the 2022 financial year. The Group’s net debt amounted to EUR 1,376.8 million as at 31 December 2022 (31 December 2021: EUR 1,364.8 million), while cash and cash equivalents amounted to EUR 634.6 million (31 December 2021: EUR 647.2 million). The ratio of net debt to EBITDA for the past 12 months was 3.5x (31 December 2021: 3.6x). Asklepios will respond flexibly to the expected regulatory requirements in order to mitigate the potential effects on its business activity. Thanks to strategic investments in digitalisation and the shift towards outpatient care, as well as internally financed capital expenditure on its healthcare facilities amounting to EUR 218.3 million, Asklepios has created a sound basis for weathering the challenges well in economic terms. Overall, Asklepios anticipates stable revenue growth and largely positive economic development in 2023.
IR contact PR contact
Visit Asklepios online, on Facebook or on YouTube: gesundleben.asklepios.com 28.04.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. 1619907 28.04.2023 CET/CEST Source : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière